Investigates gold-catalyzed release of amines in targeted cancer therapies, suggesting potential in drug design.
applications, particularly with the development of prodrug strategies. This work introduces the ethynylated biarylbutanamide (EBB) group, which was designed to undergo gold-catalyzed hydrothiolation, cyclization, and hydrolysis to release amines under mild physiological conditions. To highlight its application for anticancer prodrug therapies, this study then utilized lectin-directed artificial metalloenzymes for the gold-catalyzed activation of an EBB-masked prodrug against targeted hypersialylated cancer cells.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: